Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire
Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025
Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025
Management will host a conference call and webcast today at 8:30 am ET
Management will host a conference call accompanied by a slide presentation to provide a corporate update focused on Equillium’s retention of rights to itolizumab, for analysts and institutional investors, at 8:30 am ET today, October 31, 2024. To access the call, please dial (800) 715-9871 or (646) 307-1963 for international callers, and if needed provide conference ID number 2574379. A live webcast of the call will also be available on the company’s Investor Relations page. The webcast will be archived for 180 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.